Imagine having a set of molecular LEGO bricks that can be quickly reshaped to fit and block any virus. Instead of starting from scratch for every new disease, this system uses AI to design small human-like proteins that act as shields. These shields can be swapped and tweaked rapidly to stop viruses like the flu or COVID-19 from entering cells.
Traditional antiviral development is too slow to keep up with rapidly mutating viruses and emerging pandemics. This leads to devastating public health and economic losses due to lack of preparedness.
A computational and experimental platform for designing, producing, and validating monobody proteins. This includes a high-throughput screening system and GMP production protocols for Phase I trials.
If you are a drug discovery firm dealing with the slow pace of antiviral development — this project developed a computational design platform that allows for the rapid creation of customized proteins. This reduces the time needed to target newly emerging pandemic viruses and variants.
If you are a CDMO dealing with complex protein production — this project developed a method using simple bacterial expression for monobodies. This simplifies the manufacturing process for high-potency neutralizing candidates.
If you are a health agency dealing with pandemic unpreparedness — this project developed a broad-spectrum antiviral platform. It provides a portfolio of validated drugs for Influenza A, SARS-CoV-2, respiratory syncytial virus, and Zika virus.
Based on available project data, specific pricing or cost structures for the platform are not provided.
The project utilizes simple bacterial expression and aims for GMP production to ensure the proteins can be manufactured for clinical use.
Based on available project data, specific patent or licensing terms are not mentioned, though the project involves 11 partners including 3 industry members.
The project focuses on 'rapidly adaptable' and 'streamlined' preclinical validation to accelerate the selection of neutralizing candidates.
It integrates deep learning and computational design with cryo-EM and high-throughput screening to move from design to Phase I clinical trials.
The consortium is well-balanced for translation, consisting of 11 partners across 8 countries. With a 27% industry ratio (3 companies, including 4 SMEs), there is a clear bridge between the 3 universities and 4 research institutions and the commercial market, ensuring the platform is designed with GMP production and clinical translation in mind.
Contact UNIVERSIDADE NOVA DE LISBOA
Contact us to connect with the EvaMobs consortium for licensing opportunities.
